Loading
Biomarkers / Polycystic Ovary Syndrome (PCOS) / Micrornas (mirnas) · Journal article
Clinica Chimica Acta; International Journal of Clinical Chemistry · June 25, 2026
A consensus or society position rather than new primary data.
This is a narrative review of PCOS pathophysiology and emerging diagnostic and prognostic biomarkers. It synthesizes knowledge on systemic biomarkers (pro-inflammatory cytokines, endotoxemia, miR-146a) and endometrial biomarkers (GLUT4, HOXA10, TNF-α) and proposes a framework for integrating biomarker profiling into clinical practice, but does not report new empirical evidence or validate the proposed framework.
Narrative review. Patients with PCOS.
Insulin resistance identified as central molecular driver of metabolic and reproductive complications in PCOS including infertility, obesity, and cardiovascular risk Systemic biomarkers such as pro-inflammatory cytokines and circulating endotoxemia proposed to provide prognostic insight into metabolic deterioration Endometrial biomarkers including GLUT4, HOXA10, and TNF-α proposed to evaluate uterine receptivity and predict ART outcomes
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review proposes a framework for personalised biomarker-informed interventions in PCOS but does not provide validated clinical evidence for any specific biomarker or intervention. Clinicians should view this as a synthesis of current understanding and conceptual framework rather than actionable guidance backed by clinical trial data.
A narrative review synthesizing current knowledge on PCOS pathophysiology and emerging biomarkers to propose a clinical framework, without reporting original empirical data or new trial results.
As stated by the source record.
This review proposes a framework for personalised biomarker-informed interventions in PCOS but does not provide validated clinical evidence for any specific biomarker or intervention. Clinicians should view this as a synthesis of current understanding and conceptual framework rather than actionable guidance backed by clinical trial data.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Polycystic ovary syndrome (PCOS) is a highly prevalent and phenotypically diverse endocrine disorder in which insulin resistance (IR) serves as a central molecular driver of major metabolic and reproductive complications, including infertility, obesity, and increased long-term cardiovascular risk. This review examines the complex pathophysiology of PCOS, emphasizing how chronic systemic low-grade inflammation, gut microbiome dysbiosis, and oxidative stress interact to worsen hyperinsulinemia and hyperandrogenemia. It also highlights the clinical value of emerging diagnostic and prognostic biomarkers to improve risk stratification and patient management. Systemic biomarkers, such as pro-inflammatory cytokines, circulating endotoxemia arising from increased intestinal permeability, and epigenetic regulators including miR-146a, may provide prognostic insight into the trajectory of metabolic deterioration. In parallel, endometrial biomarkers, including the glucose transporter GLUT4, implantation-associated genes such as HOXA10, and inflammatory mediators like TNF-α, can support evaluation of impaired uterine receptivity, prediction of assisted reproductive technology (ART) outcomes, and stratification of miscarriage risk. By mapping key interactions within the gut-immune-metabolic axis and detailing localized endometrial dysfunction, this review proposes a framework for integrating targeted biomarker profiling into clinical practice to enable personalized, biomarker-informed interventions aimed at restoring fertility and metabolic health in patients with PCOS.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.